Mon - Fri: 10:00 - 19:00
Sat, Sun: 11:00 - 17:00
001-234-5679
001-987-6543
HTIC, Inc. is proud to announce a significant milestone in its therapeutic pipeline. The company recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its first-in-class humanized monoclonal antibody designed to address NETosis-mediated immune dysregulation in human disease. On November 19, 2025, HTIC received the FDA’s “safe to…
HTIC, Inc. has recently received a new NIH Small Business Technology Transfer (STTR) award to support the development of an innovative treatment for diabetic wound healing. The project focuses on targeting excessive NETosis, a key driver of impaired wound repair in diabetic patients.
Humanized CitH3 Monoclonal Antibody Improves Respiratory Function and Attenuates Neutrophil-Mediated Inflammation in a Rodent Model of Smoke Inhalation Lung Injury. Aziz DZ, Binion CC, Xu H, Wang X, Rodgers S, Gillis DC, Ledford B, Siletzky R, Zhou X, Li Y, Cai C, Tsihlis ND, Ma J, Kibbe MR.J Am Coll Surg. 2025 Oct 6. doi: 10.1097/XCS.0000000000001620.…
Humanized Monoclonal Antibody Against Citrullinated Histone H3 Attenuates Myocardial Injury and Prevents Heart Failure in Rodent Models. Weber M, Chen Y, Zhou X, Chun H, Wu D, Park KH, Cai C, Li Y, Ma J, Yang Z.Biomolecules. 2025 Aug 20;15(8):1196. doi: 10.3390/biom15081196.PMID: 40867640 Free PMC article.
A citrullinated histone H3 monoclonal antibody for immune modulation in sepsis. Ouyang W, Chen Y, Tan T, Song Y, Dong T, Yu X, Lee KE, Zhou X, Tetz Z, Go S, Zeng X, Shao L, Quan C, Zhao T, Tian Y, Kurabayashi K, Jin H, Ma J, Qin J, Williams B, Li Q, Zhu GD,…